Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT03245541
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
🇺🇸Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
Durvalumab in DLBCL After Autologous Transplant
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Registration Number
- NCT03241017
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT03238027
- Locations
- 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2024-07-12
- Target Recruit Count
- 9
- Registration Number
- NCT03237377
- Locations
- 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2018-03-15
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Registration Number
- NCT03235869
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 54
- Registration Number
- NCT03212469
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL
- Conditions
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Singapore General Hospital
- Registration Number
- NCT03212807
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
🇸🇬Raffles Hospital, Singapore, Singapore
🇸🇬Singapore General Hospital, Singapore, Singapore
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT03204812
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT03206073
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 18
- Registration Number
- NCT03199040
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.